Note: All changes are versus the prior-year period unless otherwise stated
"Our strong first-quarter performance is the result of the continued execution of our…strategy to drive growth and bring innovative medicines to patients," CEO Paul Hudson remarked. The executive noted "Dupixent continues its outstanding performance with impressive growth in the US and strong uptake in global markets, including China."
Sanofi continues to expect business earnings per share to grow in the high-single digits this year on a CER basis.
Analysts at Bryan Garnier noted that Sanofi's first-quarter earnings were ahead of expectations despite a tough comparable period, which was boosted by patient stockpiling ahead of the COVID-19 pandemic. Meanwhile, Citi analysts suggested that the drugmaker's guidance for 2021 was increasingly looking conservative and they expect it to be raised later this year.
Sanofi disclosed that the FDA extended the target review date for its avalglucosidase alfa marketing application in Pompe disease by three months to August 18. The filing for the long-term enzyme replacement therapy had been granted priority review last year.
To read more Top Story articles, click here.